334 related articles for article (PubMed ID: 24908047)
1. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
3. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
[TBL] [Abstract][Full Text] [Related]
4. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603
[TBL] [Abstract][Full Text] [Related]
5. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
6. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
Chong H; Qiu Z; Su Y; Yang L; He Y
AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
8. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
[TBL] [Abstract][Full Text] [Related]
10. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
11. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
[TBL] [Abstract][Full Text] [Related]
12. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
Zhang X; Zhu Y; Hu H; Zhang S; Wang P; Chong H; He J; Wang X; He Y
Front Cell Infect Microbiol; 2018; 8():51. PubMed ID: 29535974
[TBL] [Abstract][Full Text] [Related]
13. Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.
Chong H; Qiu Z; Sun J; Qiao Y; Li X; He Y
Retrovirology; 2014 May; 11():40. PubMed ID: 24884671
[TBL] [Abstract][Full Text] [Related]
14. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
16. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
Su S; Ma Z; Hua C; Li W; Lu L; Jiang S
Molecules; 2017 Nov; 22(11):. PubMed ID: 29156603
[TBL] [Abstract][Full Text] [Related]
17. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.
Yao X; Chong H; Zhang C; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Feb; 287(9):6788-96. PubMed ID: 22228771
[TBL] [Abstract][Full Text] [Related]
18. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
Chong H; Yao X; Qiu Z; Qin B; Han R; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Jun; 287(24):20281-9. PubMed ID: 22511760
[TBL] [Abstract][Full Text] [Related]
19. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q
J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584
[TBL] [Abstract][Full Text] [Related]
20. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
